지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2019.4
- 수록면
- 201 - 207 (7page)
이용수
초록· 키워드
오류제보하기
Nanoxel-PM™ (Nanoxel) is a docetaxel-loaded methoxy-poly(ethylene glycol)-block-poly(D,L-lactide) (mPEGPDLLA). This newly developed and marketed nanoformulation exhibits an improved pharmacokinetic profile, efficacy, and safety. Although the safety of Nanoxel to docetaxel as well as its bioequivalence must be clinically confirmed, all biological activities have not been examined in in vitro or in vivo studies. Here, the toxicity in a cultured cell system and the effects on blood cells were tested with Nanoxel and docetaxel. The in vitro cytotoxicity of Nanoxel was found to be comparable to or slightly lower than that of docetaxel depending on the concentrations tested or the cell types. Neither docetaxel nor Nanoxel induced erythrocytes hemolysis and produced reactive oxygen species up to 100 μM. However, Nanoxel was able to enhance the aggregatory response of platelets to collagen, whereas docetaxel attenuated such aggregation in a range of 50-100 μM, while thrombin-induced aggregation was not affected by either of them. Docetaxel or Nanoxel did not alter basal level of Ca<SUP>2+</SUP> and 5-hydroxytryptamine-evoked Ca<SUP>2+</SUP> transient in vascular smooth muscle cells. These results suggest that the mPEG-PDLLA micellar formulation alters the toxicological properties of docetaxel, and that extra cautions are needed when evaluating the safety of nanomedicine.
목차
Abstract
INTRODUCTION
MATERIALS AND METHODS
RESULT
DISCUSSION
REFERENCES
참고문헌 (22)
참고문헌 신청
Takimoto, C.H. / 2008 / The Role of Microtubules in Cell Biology, Neurobiology, and Oncology / Humana Press :395~419
Herbst, R.S. / 2003 / Mode of action of docetaxel - a basis for combination with novel anticancer agents / Cancer Treat. Rev 29:407~415
Clarke, S.J. / 1999 / Clinical pharmacokinetics of docetaxel / Clin. Pharmacokinet 36:99~114
Kenmotsu, H. / 2015 / Pharmacokinetics, dynamics and toxicity of docetaxel: why the Japanese dose differs from the Western dose / Cancer Sci 106:497~504
Yanasarn, N. / 2009 / Nanoparticles engineered from lecithin-in-water emulsions as a potential delivery system for docetaxel / Int. J. Pharm 379:174~180
Herbst, R.S. / 2003 / Mode of action of docetaxel - a basis for combination with novel anticancer agents / Cancer Treat. Rev 29:407~415
Clarke, S.J. / 1999 / Clinical pharmacokinetics of docetaxel / Clin. Pharmacokinet 36:99~114
Kenmotsu, H. / 2015 / Pharmacokinetics, dynamics and toxicity of docetaxel: why the Japanese dose differs from the Western dose / Cancer Sci 106:497~504
Yanasarn, N. / 2009 / Nanoparticles engineered from lecithin-in-water emulsions as a potential delivery system for docetaxel / Int. J. Pharm 379:174~180
함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
A Multi-Center Trial to Evaluate the Safety and Toxicity of Nanoxel®-M in Breast Cancer Patients
Journal of Breast Disease
2021 .12
-
Nanomedicine-based commercial formulations: current developments and future prospects
Journal of Pharmaceutical Investigation
2023 .01
-
Docetaxel-Aggravated Psoriasis
Annals of Dermatology
2019 .01
-
Therapeutic efficacy of nanomedicines for prostate cancer: An update
Investigative and Clinical Urology
2016 .01
-
Nanomedicines: current status and future perspectives in aspect of drug delivery and pharmacokinetics
Journal of Pharmaceutical Investigation
2018 .01
-
Effects of combination therapy of docetaxel with selenium on the human breast cancer cell lines MDA-MB-231 and MCF-7
Annals of Surgical Treatment and Research
2015 .01
-
Genetic Variations of Drug Transporters Can Influence on Drug Response in Patients Treated with Docetaxel Chemotherapy
Cancer Research and Treatment
2015 .01
-
ABT-737 ameliorates docetaxel resistance in triple negative breast cancer cell line
Annals of Surgical Treatment and Research
2018 .11
-
ERRATUM: Caveolin-1 Modulates Docetaxel-Induced Cell Death in Breast Cancer Cell Subtypes through Different Mechanisms
Cancer Research and Treatment
2019 .01
-
Docetaxel rechallenge in metastatic castration-resistant prostate cancer: A retrospective, single-center study
Investigative and Clinical Urology
2020 .01
-
East Asian Subgroup Analysis of a Randomized, Double-Blind, Phase 3 Study of Docetaxel and Ramucirumab Versus Docetaxel and Placebo in the Treatment of Stage IV Non-small Cell Lung Cancer Following Disease Progression after One Prior Platinum-Based Therapy (REVEL)
Cancer Research and Treatment
2016 .01
-
Nanomedicines for oral administration based on diverse nanoplatform
Journal of Pharmaceutical Investigation
2016 .07
-
Circulating Plasma Biomarkers for TSU-68, an Oral Antiangiogenic Agent, in Patients with Metastatic Breast Cancer
Cancer Research and Treatment
2016 .01
-
Nanomedicine-based antimicrobial peptide delivery for bacterial infections: recent advances and future prospects
Journal of Pharmaceutical Investigation
2021 .01
-
Application of molecular dynamics simulation in self-assembled cancer nanomedicine
생체재료학회지
2023 .03
-
Evaluation the Use of Frozen Sock to Prevent Docetaxel-Induced Peripheral Neuropathy in Breast Cancer Patients
대한외과학회 학술대회 초록집
2018 .11
-
Effectiveness of Adding Docetaxel to Androgen Deprivation Therapy for Metastatic Hormone-Sensitive Prostate Cancer in Korean Real-World Practice
Yonsei Medical Journal
2023 .02
-
Analysis on Breast Cancer Refractory to Neoadjuvant Docetaxel Chemotherapy Following Adriamycin and Cyclophosphamide
대한외과학회 학술대회 초록집
2020 .11
-
Safety Analysis of Adjuvant Chemotherapy with Docetaxel Administered with or without Anthracyclines to Early Stage Breast Cancer Patients: Combined Results from the Asia-Pacific Breast Initiatives I and II
Asian Pacific journal of cancer prevention : APJCP
2016 .01
-
A Single-Arm, Prospective, Phase II Study of Cisplatin Plus Weekly Docetaxel as First-Line Therapy in Patients with Metastatic or Recurrent Salivary Gland Cancer
Cancer Research and Treatment
2022 .07
이 논문의 저자 정보
최근 본 자료
댓글(0)
0
UCI(KEPA) : I410-ECN-0101-2019-513-000530528